Publications by authors named "Sadie Roberts"

Claim this Profile
A
An open-source repository-based tool for quality control of imaging protocol compliance: demonstration in a multicentre MRI study.
Sam Keaveney, Damien J McHugh, Mihaela Rata, Alina Dragan, Jessica M Winfield, Sadie Roberts

Br J Radiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
Sam Keaveney, Alina Dragan, Mihaela Rata, Matthew Blackledge, Erica Scurr, Sadie Roberts

Insights Imaging· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Martin F Kaiser, Andrew Hall, Katrina Walker, Amy Sherborne, Ruth M De Tute, Sadie Roberts

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Sian E Faustini, Andrew Hall, Sarah Brown, Sadie Roberts, Harriet Hill

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Jessica Kendall, Andrew Hall, Sadie Roberts, Sarah Brown, Kevin Boyd

BMJ Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
Mihaela Rata, Matthew Blackledge, Erica Scurr, Jessica Winfield, Dow-Mu Koh, Sadie Roberts

Insights Imaging· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
Holger W Auner, Sarah R Brown, Katrina Walker, Jessica Kendall, Bryony Dawkins, Sadie Roberts

Blood Cancer J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
Sarah Brown, Debbie Sherratt, Samantha Hinsley, Louise Flanagan, Sadie Roberts

BMJ Open· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis